SUDA Ltd (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia. The Company is developing low-risk oral sprays using novel formulations of existing off-patent pharmaceuticals. The many potential benefits of administering drugs through the oral mucosa (ie: cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. Suda’s most advanced product is a novel sub-lingual treatment, ArTiMist®, for severe malaria in children. In a Phase III trial, ArTiMist® was shown to be superior to intravenous quinine. Other development stage products include orals sprays for the treatment of migraine headache, erectile dysfunction and chemotherapy-induced nausea and vomiting.